You are here: Home » News-IANS » Health-Medicine
Business Standard

Biocon to soon market breast cancer drug in Canada

IANS  |  Bengaluru 

Biotech on Wednesday said it would soon market in its anti-drug Ogivri, which it co-developed with the US-based Mylan, following approval by the Canadian health regulator.

"As is the first drug approved by Health and the second biosimilar co-developed with Mylan, we plan to market it in this (first) quarter in as an affordable treatment option for patients," said the company in a statement.

The drug can also be used to treat "The approval will pave the way for the drug's commercialisation by our partner Thousands of patients in Europe, and key emerging markets are benefiting from it," said the statement.

Biocon's biologics arm is committed to address the unmet patient needs through affordable medicines, globally. The biosimilar has approval in 65 countries, including the US.

"As a in making drugs, including biosimilar medicines, the Canadian approval is a milestone for Ogivri, which is an important treatment option to market for Canadian patients," said Mylan's

The regulatory approval was based on data from structural and functional characterisation using multiple orthogonal techniques, non-clinical studies and pharma-cokinetic evaluation in healthy subjects.

The data showed that is similar to Herceptin with no clinical differences in terms of efficacy, safety, purity and potency.



(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, May 22 2019. 19:58 IST